Caribou Biosciences Inc [CRBU] stock is trading at $1.42, up 5.19%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRBU shares have gain 7.58% over the last week, with a monthly amount drifted -7.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Caribou Biosciences Inc [NASDAQ: CRBU] stock has seen the most recent analyst activity on June 03, 2024, when Evercore ISI downgraded its rating to a In-line and also revised its price target to $3 from $13. On October 31, 2023, Evercore ISI initiated with a Outperform rating and assigned a price target of $13 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $23 on July 11, 2023. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $22 as its price target on February 18, 2022. Oppenheimer started tracking with a Outperform rating for this stock on December 01, 2021, and assigned it a price target of $36. In a note dated November 30, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $28 on this stock.
Caribou Biosciences Inc [CRBU] stock has fluctuated between $1.22 and $8.33 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Caribou Biosciences Inc [NASDAQ: CRBU] shares were valued at $1.42 at the most recent close of the market. An investor can expect a potential return of 111.27% based on the average CRBU price forecast.
Analyzing the CRBU fundamentals
Caribou Biosciences Inc [NASDAQ:CRBU] reported sales of 11.47M for the trailing twelve months, which represents a drop of -91.45%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -14.4%, Pretax Profit Margin comes in at -12.89%, and Net Profit Margin reading is -12.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.45 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3467 points at the first support level, and at 1.2733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4767, and for the 2nd resistance point, it is at 1.5333.
Ratios To Look Out For
For context, Caribou Biosciences Inc’s Current Ratio is 7.38. Also, the Quick Ratio is 7.38, while the Cash Ratio stands at 0.99. Considering the valuation of this stock, the price to sales ratio is 11.21, the price to book ratio is 0.46.
Transactions by insiders
Recent insider trading involved Ryali Sriram, Chief Financial Officer, that happened on Jan 29 ’25 when 17360.0 shares were purchased.
